25 results on '"Mizukami, Takuro"'
Search Results
2. Decision making for anti-VEGF inhibitor continuation: dip stick? or urine protein/creatinine ratio? (VERSiON UP study)
- Author
-
Nakamura, Michio, Funakoshi, Taro, Kataoka, Shigeki, Horimatsu, Takahiro, Nishikawa, Yoshitaka, Matsubara, Takeshi, Mizukami, Takuro, Goto, Tomoyuki, Tsuchihashi, Kenji, Baba, Eishi, Tsumura, Takehiko, Mihara, Yoshiaki, Hamaguchi, Tetsuya, Yanagita, Motoko, and Muto, Manabu
- Published
- 2022
- Full Text
- View/download PDF
3. Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild‐type metastatic colorectal cancer: A phase II trial (HYBRID).
- Author
-
Arai, Hiroyuki, Tsuda, Takashi, Sunakawa, Yu, Shimokawa, Mototsugu, Akiyoshi, Kohei, Tokunaga, Shinya, Shoji, Hirokazu, Kunieda, Kenji, Kotaka, Masahito, Matsumoto, Toshihiko, Nagata, Yusuke, Mizukami, Takuro, Mizuki, Fumitaka, Danenberg, Kathleen D., Boku, Narikazu, and Nakajima, Takako Eguchi
- Subjects
CANCER chemotherapy ,COLORECTAL cancer ,METASTASIS ,BEVACIZUMAB ,CETUXIMAB ,ACNEIFORM eruptions - Abstract
Background: Long‐term anti‐EGFR antibody treatment increases the risk of severe dermatologic toxicities. This single‐arm, phase II trial aimed to investigate the strategy of switching from cetuximab to bevacizumab in combination with FOLFIRI based on early tumor shrinkage (ETS) in patients with RAS wild‐type metastatic colorectal cancer (mCRC). Methods: Radiologic assessment was performed to evaluate ETS, defined as ≥20% reduction in the sum of the largest diameters of target lesions 8 weeks after the introduction of FOLFIRI plus cetuximab. ETS‐negative patients switched to FOLFIRI plus bevacizumab, whereas ETS‐positive patients continued FOLFIRI plus cetuximab for eight more weeks, with a switch to FOLFIRI plus bevacizumab thereafter. The primary endpoint was progression‐free survival. Results: This trial was prematurely terminated due to poor accrual after a total enrollment of 30 patients. In 29 eligible patients, 7 were ETS‐negative and 22 were ETS‐positive. Two ETS‐negative patients and 17 ETS‐positive patients switched to FOLFIRI plus bevacizumab 8 weeks and 16 weeks after initial FOLFIRI plus cetuximab, respectively. Median progression‐free and overall survival durations were 13.4 and 34.7 months, respectively. Six (20%) patients experienced grade ≥3 paronychia, which improved to grade ≤2 by 18 weeks. Grade ≥3 acneiform rash, dry skin, and pruritus were not observed in any patients. Conclusions: Our novel treatment strategy delivered acceptable survival outcomes and reduced severe dermatologic toxicities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan
- Author
-
Funakoshi, Taro, Horimatsu, Takahiro, Nakamura, Michio, Shiroshita, Koichi, Suyama, Koichi, Mukoyama, Masashi, Mizukami, Takuro, Sakurada, Tsutomu, Baba, Eishi, Tsuruya, Kazuhiko, Nozaki, Akira, Yahata, Kensei, Ozaki, Yukinori, Ubara, Yoshifumi, Yasui, Hisateru, Yoshimoto, Akihiro, Fukuma, Shingo, Kondo, Naoya, Matsubara, Takeshi, Matsubara, Kazuo, Fukuhara, Shunichi, Yanagita, Motoko, and Muto, Manabu
- Published
- 2018
- Full Text
- View/download PDF
5. A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: the NEXTAC-TWO study protocol
- Author
-
Miura, Satoru, Naito, Tateaki, Mitsunaga, Shuichi, Omae, Katsuhiro, Mori, Keita, Inano, Toshimi, Yamaguchi, Teiko, Tatematsu, Noriatsu, Okayama, Taro, Morikawa, Ayumu, Mouri, Takako, Tanaka, Hisashi, Kimura, Madoka, Imai, Hisao, Mizukami, Takuro, Imoto, Akira, Kondoh, Chihiro, Shiotsu, Shinsuke, Okuyama, Hiroyuki, Ueno, Makoto, Takahashi, Toshiaki, Tsuji, Tetsuya, Aragane, Hideki, Inui, Akio, Higashiguchi, Takashi, and Takayama, Koichi
- Published
- 2019
- Full Text
- View/download PDF
6. Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study
- Author
-
Booka, Eisuke, Imamura, Chiyo K., Takeuchi, Hiroya, Hamamoto, Yasuo, Gomi, Daisuke, Mizukami, Takuro, Ichiyama, Takashi, Tateishi, Kazunari, Takahashi, Tsunehiro, Kawakubo, Hirofumi, Soejima, Kenzo, Boku, Narikazu, Tanigawara, Yusuke, and Kitagawa, Yuko
- Published
- 2016
- Full Text
- View/download PDF
7. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
- Author
-
Umemoto, Kumiko, Yamamoto, Hiroyuki, Oikawa, Ritsuko, Takeda, Hiroyuki, Doi, Ayako, Horie, Yoshiki, Arai, Hiroyuki, Ogura, Takashi, Mizukami, Takuro, Izawa, Naoki, Moore, Jay A, Sokol, Ethan S, and Sunakawa, Yu
- Abstract
Background: Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens. Recently, tumor-agnostic approaches have been developed for some targeted therapies in advanced solid tumors; however, the frequency of alterations by clinical and genomic background is unclear in PC and BTC.Methods: To assess the frequencies of druggable gene alterations and investigate new potential therapeutic targetable genomic alterations, advanced PC and BTC patients were tested with comprehensive genomic profiling at Foundation Medicine during the course of clinical care.Results: A total of 16 913 PC patients and 3031 BTC patients were available for analyses, and frequencies of genomic alterations were stratified by age (≥40 years or <40 years), microsatellite instability status, tumor mutational burden status (high ≥10 or low <10 Muts/Mb), and select genomic alterations. Alterations in BRCA2, BRAF, ERBB2, CDK12, PIK3CA, FGFR2, EGFR, and other potential targets were seen across cohorts, with enrichment observed within particular subsets such as in PC patients lacking a KRAS mutation. In BTC patients, the rate of ERBB2 amplification was statistically significantly higher in the tumor mutational burden-high population (23.3% vs 13.7%). Interestingly, CDK12 rearrangement was observed in BTC patients with ERBB2 amplification tumors. In patients younger than 40 years, FGFR2 rearrangement (4%) was observed in PC: GATA6 amplification (11.1%) and rearrangement of BRAF (2.8%)FGFR2 (5.6%) was observed in BTC patients.Conclusions: We identified an appreciable frequency of immunotherapy biomarkers and targetable gene alterations in both PC and BTC, with notable frequencies in PC samples lacking KRAS mutations and children or adolescent and young adult populations, that should encourage comprehensive genomic profiling testing. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial chemotherapy (GASPACHO study): a multicenter retrospective study.
- Author
-
Azemoto, Nobuaki, Ueno, Makoto, Yanagimoto, Hiroaki, Mizuno, Nobumasa, Kawamoto, Yasuyuki, Maruki, Yuta, Watanabe, Kazuo, Suzuki, Rei, Kaneko, Junichi, Hisada, Yuya, Sato, Hiroki, Kobayashi, Satoshi, Miyata, Hideki, Furukawa, Masayuki, Mizukami, Takuro, Miwa, Haruo, Ohno, Yoshinori, Tsuji, Kunihiro, Tsujimoto, Akiko, and Nagano, Hiroaki
- Published
- 2022
- Full Text
- View/download PDF
9. Prediction of esophagogastric varices associated with oxaliplatin administration.
- Author
-
Satta, Yosuke, Shigefuku, Ryuta, Watanabe, Tsunamasa, Mizukami, Takuro, Tsuda, Takashi, Suzuki, Tatsuya, Ehira, Takuya, Hattori, Nobuhiro, Kiyokawa, Hirofumi, Nakahara, Kazunari, Ikeda, Hiroki, Matsunaga, Kotaro, Takahashi, Hideaki, Matsumoto, Nobuyuki, Okuse, Chiaki, Suzuki, Michihiro, Sunakawa, Yu, Yasuda, Hiroshi, and Itoh, Fumio
- Subjects
COMPUTED tomography ,RECEIVER operating characteristic curves ,COLORECTAL cancer ,OXALIPLATIN ,SENSITIVITY & specificity (Statistics) - Abstract
Background: Oxaliplatin is a key drug for the chemotherapy of colorectal cancer; however, it is also known to cause non‐cirrhotic portal hypertension. We aimed to identify the characteristics of patients who developed esophagogastric varices (EGVs) after treatment with oxaliplatin. Methods: This study retrospectively analyzed patients with colorectal cancer who were treated with chemotherapy including oxaliplatin between 2010 and 2016. All patients were evaluated by contrast‐enhanced computed tomography (CE‐CT) every 3 months both during and after treatment; and endoscopy was performed when appearance of portal hypertension was suspected. Results: A total of 106 patients were divided into two groups: EGV formation (n = 6) and EGV non‐formation (n = 100). In the EGV group, platelet counts decreased and the size of the spleen calculated by CT (CT spleen index; CT‐SI) increased markedly. The highest area under the receiver operating characteristic curve (AUC) for the change in platelet counts was 0.81 (80% sensitivity and 83% specificity) at 3 months post treatment, and the maximum AUC for CT‐SI was 0.89 (79% sensitivity and 83% specificity) at 6 months post treatment. Conclusions: EGV formation could be predicted by the assessment of platelet counts and spleen size. If progressive splenomegaly and thrombocytopenia are observed not only during but also after completion of the oxaliplatin‐containing chemotherapy, EGVs should be confirmed by endoscopy for avoiding subsequent rupture. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. O1-6 REVIVE study: An observational study in chemotherapy (CTx) after nivolumab (NIVO) for advanced gastric cancer (AGC)
- Author
-
Sakamoto, Yasuhiro, Narita, Yukiya, Misumi, Toshihiro, Matsuoka, Hiroshi, Tanioka, Hiroaki, Kawakami, Takeshi, Matsushima, Tomohiro, Miwa, Hiroto, Shoji, Hirokazu, Ishiguro, Atsushi, Fushida, Sachio, Miura, Kou, Yamada, Takanobu, Shinozaki, Katsunori, Mizukami, Takuro, Nishina, Tomohiro, Moriwaki, Toshikazu, Mitani, Seiichiro, Nakamura, Michio, and Muro, Kei
- Published
- 2022
- Full Text
- View/download PDF
11. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer.
- Author
-
Mizukami, Takuro and Piao, Yongzhe
- Abstract
Patients with advanced or metastatic gastric cancer often suffer from malnutrition, which can have an impact on quality of life, increase the toxicity of chemotherapy and reduce overall survival. Options available to the clinician to manage a patient's nutritional status include screening and assessment of malnutrition at diagnosis, monitoring during the 'cancer journey', early detection of precachexia and the ongoing use of a multidisciplinary team (oncologists, other medical specialists and nutritionists). Because malnutrition is frequently overlooked and under treated in patients with advanced or metastatic gastric cancer, this narrative review focuses on the clinical meaning of nutritional status in gastric cancer and provides general guidance regarding nutritional care management for patients with advanced or metastatic gastric cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. An observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
- Author
-
Mizukami, Takuro, Miyaji, Tempei, Narita, Yukiya, Matsushima, Tomohiro, Ogura, Takashi, Miyagaki, Hiromichi, Kawabata, Ryohei, Horie, Yoshiki, Kawaguchi, Takashi, Muro, Kei, Hara, Hiroki, Yamaguchi, Takuhiro, E Nakajima, Takako, and E Nakajima, Takako
- Subjects
MALNUTRITION diagnosis ,MALNUTRITION treatment ,STOMACH tumors ,RESEARCH ,ANTINEOPLASTIC agents ,MONOCLONAL antibodies ,MEDICAL cooperation ,TUMOR classification ,DIET therapy ,MALNUTRITION ,PACLITAXEL ,LONGITUDINAL method ,NUTRITIONAL status ,DISEASE complications - Abstract
Limited data are available regarding the efficacy of nutrition support in advanced gastric cancer (AGC) patients receiving a standard second-line combination chemotherapy. The BALAST study is conducted as a prospective, multicenter observational study to evaluate the efficacy of nutrition support for patients with AGC treated with ramucirumab plus taxane as second-line treatment. As part of the routine care, patients who are malnourished or at risk of malnutrition will receive nutrition support from dietitians. We will enroll a total of 26 patients to estimate weight control rate at 12 weeks as primary end point. This study will generate valuable data reinforcing the role of nutrition support therapy for AGC patients receiving second-line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
- Author
-
Narita, Yukiya, Shoji, Hirokazu, Kawai, Sadayuki, Mizukami, Takuro, Nakamura, Michio, Moriwaki, Toshikazu, Yamanaka, Takeharu, Sunakawa, Yu, Kawakami, Hisato, Nishina, Tomohiro, Misumi, Toshihiro, and Muro, Kei
- Abstract
Nivolumab is an increasingly used standard care treatment for heavily pretreated patients with advanced gastric cancer, with increasing clinical use in Japan. Data from retrospective studies on various tumors have shown the objective response rate to cytotoxic chemotherapy potentially improves after an exposure to immune checkpoint inhibitors. Based on these data, we conducted the multicenter observational REVIVE study to evaluate the efficacy and safety of cytotoxic chemotherapy in nivolumab-refractory or nivolumab-intolerant patients with advanced gastric cancer. Patients who are refractory or intolerant to nivolumab and scheduled to receive irinotecan monotherapy, oxaliplatin combination treatment or oral trifluridine/tipiracil hydrochloride therapy will be included. The primary end point is overall survival of nivolumab-pretreated patients with advanced gastric cancer after the cytotoxic chemotherapy. Clinical trial registration: UMIN000032182 (umin.ac.jp). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Prospective evaluation and refinement of an S‐1 dosage formula based on renal function for clinical application.
- Author
-
Takeuchi, Masashi, Imamura, Chiyo K., Booka, Eisuke, Takeuchi, Hiroya, Mizukami, Takuro, Kawakami, Takeshi, Funakoshi, Taro, Wakuda, Kazushige, Aoki, Yu, Hamamoto, Yasuo, Kitago, Minoru, Kawakubo, Hirofumi, Boku, Narikazu, Tanigawara, Yusuke, and Kitagawa, Yuko
- Abstract
In patients with impaired renal function, S‐1–related toxicities increase due to higher exposure of 5‐fluorouracil (5‐FU). Our previous pharmacokinetic study in 16 cancer patients with various renal functions developed an S‐1 dosage formula based on individual creatinine clearance (CLcr) and body surface area (BSA). To evaluate and refine the formula, this prospective study was conducted. Thirty‐three patients with various renal functions received S‐1 for 4 weeks at doses determined by the nomogram derived from the previously developed formula. A series of blood samples were collected after the first dose to calculate the area under the concentration‐time curve (AUC) of 5‐FU. Thirty patients with BSA of 1.14‐1.84 m2 and CLcr of 23.8‐96.4 mL/min were assessable for pharmacokinetics. The observed daily AUC ranged from 712.6 to 2868.7 ng·h/mL, and 18 patients achieved the target AUC (1447.8 ± 545.4 ng·h/mL). Three patients experienced S‐1–related grade 3 adverse events during the first course. In the population pharmacokinetic analysis from the combined data of 46 patients in this study and the previous study, sex was identified as a statistically significant covariate for 5‐FU clearance. Hence, the refined formula includes sex as an additional factor: Recommended daily dose = target AUC × (14.5 + 8.23 × SEX [0 for female and 1 for male] + 0.301 × CLcr) × BSA. Revised nomograms for recommended daily doses derived from the refined formula can be used in clinical practice to achieve the target AUC ensuring efficacy and safety of S‐1. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients
- Author
-
Oguri, Tomoyo, Takeda, Hiroyuki, Umemoto, Kumiko, Doi, Ayako, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, and Sunakawa, Yu
- Published
- 2021
- Full Text
- View/download PDF
16. MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients
- Author
-
Doi, Ayako, Takeda, Hiroyuki, Umemoto, Kumiko, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Oguri, Tomoyo, and Sunakawa, Yu
- Published
- 2021
- Full Text
- View/download PDF
17. Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy
- Author
-
Sunakawa,Yu, Izawa,Naoki, Mizukami,Takuro, Horie,Yoshiki, Hirakawa,Mami, Arai,Hiroyuki, Ogura,Takashi, Tsuda,Takashi, and Nakajima,Takako
- Subjects
OncoTargets and Therapy - Abstract
Yu Sunakawa, Naoki Izawa, Takuro Mizukami, Yoshiki Horie, Mami Hirakawa, Hiroyuki Arai, Takashi Ogura, Takashi Tsuda, Takako Eguchi Nakajima Department of Clinical Oncology, St Marianna University School of Medicine, Kawasaki, Japan Abstract: TAS-102, with its robust survival efficacy and feasible toxicity, is one of the standard salvage-line treatments for patients with metastatic colorectal cancer (mCRC). No definitive data are available to determine which drug should be administered first during salvage-line treatment. Therefore, it is imperative that we establish the sequence of administration by considering drug toxicity profiles based on patient characteristics, such as age, performance status, comorbidities, tolerability to previous treatments, and patient preferences. The identification of predictive biomarkers in response to TAS-102 or its toxicity is urgently needed for better patient selection. Moreover, to strengthen efficacy or relieve toxicity, combinations with other agents, which could potentially emerge as standard treatment regimens, have been investigated and compared to existing active regimens for mCRC. Keywords: TAS-102, metastatic colorectal cancer, regorafenib, biomarker
- Published
- 2017
18. MO3-10-2 - Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients
- Author
-
Izawa, Naoki, Shiokawa, Hisae, Onuki, Risa, Hamaji, Koki, Furuya, Naoki, Ohashi, Hiroyuki, Nishi, Tomohiro, Kasugai, Shigeru, Arai, Hiroyuki, Doi, Ayako, Horie, Yoshiki, Hirakawa, Mami, Mizukami, Takuro, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu, and Nakajima, Takako
- Published
- 2019
- Full Text
- View/download PDF
19. Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer.
- Author
-
Doi A, Mizukami T, Takeda H, Umemoto K, Arai H, Horie Y, Izawa N, Ogura T, and Sunakawa Y
- Abstract
Background: Geriatric 8 (G8) and instrumental activities of daily living (IADL) are recommended to predict overall survival (OS) or risk of serious adverse events (SAEs) in older cancer patients. However, the clinical utility is relatively unknown in older patients suffering malnutrition with gastrointestinal (GI) cancer, including gastric cancer (GC) and pancreatic cancer (PC)., Materials and Methods: We retrospectively included patients aged ≥65 years with GC, PC, and colorectal cancer (CRC) who received a G8 questionnaire at first visit from April 2018 to March 2020. The associations between G8/IADL and safety or OS were assessed in patients with advanced/unresectable tumors., Results: Of 207 patients (median age: 75 years), the median G8 score was 10.5 and normal G8 score rate was 6.8%. Both the median G8 score and normal G8 (>14) score rate numerically increased in the order of GC < PC < CRC. There was no clear association between the G8 standard cutoff value of 14 and SAEs or OS. However, OS was significantly longer in patients with G8 >11 than in those with G8 ≤11 (19.3 vs. 10.5 months, p = 0.0017). Furthermore, OS was significantly better in patients with normal IADL than in those with abnormal IADL (17.6 vs. 11.4 months, p = 0.049)., Conclusion: The G8 cutoff value of 14 would not be clinically useful in patients with GI cancer for predicting OS or SAEs; however, the cutoff value of 11 and IADL may be useful to predict OS for older patients with GI cancers including GC and PC., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Doi, Mizukami, Takeda, Umemoto, Arai, Horie, Izawa, Ogura and Sunakawa.)
- Published
- 2023
- Full Text
- View/download PDF
20. The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling.
- Author
-
Umemoto K, Yamamoto H, Oikawa R, Takeda H, Doi A, Horie Y, Arai H, Ogura T, Mizukami T, Izawa N, Moore JA, Sokol ES, and Sunakawa Y
- Subjects
- Adolescent, Adult, Biomarkers, Tumor genetics, Child, Genomics, Humans, Mutation, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras) genetics, Young Adult, Pancreatic Neoplasms, Gastrointestinal Neoplasms, Proto-Oncogene Proteins B-raf genetics
- Abstract
Background: Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens. Recently, tumor-agnostic approaches have been developed for some targeted therapies in advanced solid tumors; however, the frequency of alterations by clinical and genomic background is unclear in PC and BTC., Methods: To assess the frequencies of druggable gene alterations and investigate new potential therapeutic targetable genomic alterations, advanced PC and BTC patients were tested with comprehensive genomic profiling at Foundation Medicine during the course of clinical care., Results: A total of 16 913 PC patients and 3031 BTC patients were available for analyses, and frequencies of genomic alterations were stratified by age (≥40 years or <40 years), microsatellite instability status, tumor mutational burden status (high ≥10 or low <10 Muts/Mb), and select genomic alterations. Alterations in BRCA2, BRAF, ERBB2, CDK12, PIK3CA, FGFR2, EGFR, and other potential targets were seen across cohorts, with enrichment observed within particular subsets such as in PC patients lacking a KRAS mutation. In BTC patients, the rate of ERBB2 amplification was statistically significantly higher in the tumor mutational burden-high population (23.3% vs 13.7%). Interestingly, CDK12 rearrangement was observed in BTC patients with ERBB2 amplification tumors. In patients younger than 40 years, FGFR2 rearrangement (4%) was observed in PC: GATA6 amplification (11.1%) and rearrangement of BRAF (2.8%)FGFR2 (5.6%) was observed in BTC patients., Conclusions: We identified an appreciable frequency of immunotherapy biomarkers and targetable gene alterations in both PC and BTC, with notable frequencies in PC samples lacking KRAS mutations and children or adolescent and young adult populations, that should encourage comprehensive genomic profiling testing., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
21. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report.
- Author
-
Doi A, Takeda H, Umemoto K, Oumi R, Wada S, Hamaguchi S, Mimura H, Arai H, Horie Y, Mizukami T, Izawa N, Ogura T, Nakajima TE, and Sunakawa Y
- Abstract
Background: Fistula formation is a severe adverse event related to antiangiogenetic agents such as bevacizumab and inferior mesenteric arteriovenous fistula (IMAVF) is a result of acquired factor, especially colon surgery. However, IMAVF occurs very rarely and there are few reports in patients during chemotherapy. We report a case of a patient who developed IMAVF during treatment with bevacizumab in metastatic colorectal cancer (mCRC) after colon surgery., Case Summary: An 81-year-old man was diagnosed with descending colon cancer and underwent left hemicolectomy without any complications. He was definitely diagnosed with high-risk stage 2 and received tegafur-uracil plus leucovorin as adjuvant chemotherapy. Three years and 6 mo after the operation, the cancer relapsed with peritoneal dissemination. The patient underwent CyberKnife radiosurgery targeting the recurrent tumor and received chemotherapy with S-1 plus bevacizumab. At 1 year after chemotherapy, he complained of severe diarrhea, which is suspected drug-induced colitis. As diarrhea worsened despite the termination of treatment, he underwent colonoscopy and computed tomography (CT) scans that revealed edematous change from sigmoid to rectosigmoid colon. CT scans also revealed an aneurysm adjacent to the inferior mesenteric vein and multidetector CT angiography showed the IMAVF. Elective angiography confirmed the diagnosis of an IMAVF and it was successfully treated by arterial embolization. The patient resumed chemotherapy with only S-1 6 mo after embolization., Conclusion: Clinicians should keep in mind the probability of severe diarrhea arose from IMAVF in mCRC patients treated with bevacizumab., Competing Interests: Conflict-of-interest statement: The authors declare no potential financial interests., (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
22. Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.
- Author
-
Arai H, Miyakawa K, Denda T, Mizukami T, Horie Y, Izawa N, Hirakawa M, Ogura T, Tsuda T, Sunakawa Y, and Nakajima TE
- Abstract
Background and Objective: It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib., Results: This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively., Materials and Methods: This retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC., Conclusions: EMC could be a useful predictive marker for regorafenib in mCRC., Competing Interests: CONFLICTS OF INTEREST During the conduct of the study, authors have some interests outside the submitted work as follows. Nakajima TE reports grants and personal fees from Eli Lilly Japan, grants and personal fees from Taiho Pharm., grants and personal fees from Chugai Pharm., personal fees from Sawai Pharm., grants and personal fees from Takeda Pharm., personal fees from Kyowa Hakko Kirin, grants and personal fees from Merck Sesono, personal fees from Bristol-Myers Squibb, grants and personal fees from Ono Pharm., personal fees from Bayer Yakuhin, grants and personal fees from Dainippon Sumitomo Pharm., personal fees from Maruho Co., grants from Yakult Honsha, grants from Eisai Pharm., grants from Sanofi, grants from Amgen Astellas BioPharma, grants from AstraZeneca, and grants from MSD. Denda T reports grants from Merck Serono, and grants from Boehringer Ingelheim. Sunakawa Y reports personal fees from Taiho Pharm., personal fees from Chugai Pharm., personal fees from Yakult Honsha, personal fees from Takeda Pharm., personal fees from Merck Serono, and personal fees from Bayer Yakuhin.
- Published
- 2017
- Full Text
- View/download PDF
23. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
- Author
-
Tsuda T, Kyomori C, Mizukami T, Taniyama T, Izawa N, Horie Y, Hirakawa M, Ogura T, Nakajima TE, Tsugawa K, and Boku N
- Abstract
The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.001). As an anti-emetic treatment for chemotherapy using anthracyclines, fosaprepitant may be associated with a higher risk of infusion site adverse events compared with aprepitant.
- Published
- 2016
- Full Text
- View/download PDF
24. Predictability of antitumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer following failure of fluorouracil, irinotecan and oxaliplatin.
- Author
-
Horie Y, Yamazaki K, Funakoshi T, Hamauchi S, Taniguchi H, Tsushima T, Todaka A, Machida N, Taku K, Fukutomi A, Onozawa Y, Yasui H, Mizukami T, Izawa N, Hirakawa M, Tsuda T, Nakajima T, and Boku N
- Abstract
The efficacy of cetuximab correlates with the severity of skin toxicity, although its onset may vary. The AIM of this retrospective study was to investigate the optimal observation period for skin rash as a predictor of the efficacy of cetuximab plus irinotecan. The subjects comprised 33 patients with KRAS wild-type metastatic colorectal cancer (mCRC) who had received prior chemotherapy with fluorouracil, irinotecan and oxaliplatin. The response rate (RR), progression-free survival (PFS) and overall survival (OS) were compared according to the presence or absence of ≥grade 2 skin rash within 2, 4, 6, or 8 weeks following cetuximab initiation. The overall RR was 45% (15/33) and the median PFS and OS were 188 and 383 days, respectively. A total of 26 patients experienced ≥grade 2 skin rash within 8 weeks. The proportion of responders among patients who developed ≥grade 2 skin rash (severe group) decreased depending on the duration of the observation period (50% within 8 weeks), whereas the proportion of non-responders among patients with
- Published
- 2015
- Full Text
- View/download PDF
25. MEK inhibitor for gastric cancer with MEK1 gene mutations.
- Author
-
Sogabe S, Togashi Y, Kato H, Kogita A, Mizukami T, Sakamoto Y, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Tomida S, Yasuda T, Takeyama Y, Okuno K, and Nishio K
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents pharmacology, Apoptosis drug effects, Cell Line, Cell Line, Tumor, Cell Transformation, Neoplastic genetics, Cell Transformation, Neoplastic metabolism, DNA Mutational Analysis, Disease Models, Animal, Female, Humans, Inhibitory Concentration 50, Male, Mice, Middle Aged, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, Neoplasm Staging, Phosphorylation, Protein Kinase Inhibitors chemistry, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Tumor Burden drug effects, Tumor Burden genetics, Xenograft Model Antitumor Assays, MAP Kinase Kinase 1 antagonists & inhibitors, MAP Kinase Kinase 1 genetics, Mutation, Protein Kinase Inhibitors pharmacology, Stomach Neoplasms genetics
- Abstract
The prognosis for patients with unresectable advanced or recurrent gastric cancer remains poor. The identification of additional oncogenes with influences similar to those of epidermal growth factor receptor gene mutations, upon which the growth of cancer cells is dependent, is needed. In this study, we evaluated sensitivity to MEK inhibitors (GSK1120212 and PD0325901) in several gastric cancer cell lines in vitro and found three poorly differentiated gastric cancer cell lines that were hypersensitive to the inhibitors. The sequence analyses in these three cell lines revealed that one cell line had a novel MEK1 mutation, while the other two had previously reported KRAS and MEK1 mutations, respectively; the gene statuses of the other resistant cell lines were all wild-type. Experiments using MEK1 expression vectors demonstrated that the MEK1 mutations induced the phosphorylation of ERK1/2 and had a transforming potential, enhancing the tumorigenicity. The MEK inhibitor dramatically reduced the phosphorylation of ERK1/2 and induced apoptosis in the cell lines with MEK1 mutations. In vivo, tumor growth was also dramatically decreased by an inhibitor. One of the 46 gastric cancer clinical samples that were examined had a MEK1 mutation; this tumor had a poorly differentiated histology. Considering the addiction of cancer cells to active MEK1 mutations for proliferation, gastric cancer with such oncogenic MEK1 mutations might be suitable for targeted therapy with MEK inhibitors., (©2014 American Association for Cancer Research.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.